News
FDA extends the PDUFA date for sBLA of Reblozyl in beta thalassemia.- BMS
The sBLA was based on safety and efficacy results from the pivotal Phase II BEYOND study evaluating Reblozyl plus best supportive care in adults with NTD beta thalassemia. There is an application (Type II variation) also under review by the European Medicines Agency.
Condition: Beta-thalassemia
Type: drug